ID   OCI-AML-3
AC   CVCL_1844
SY   OCI-Aml-3; OCI/AML-3; OCI-AML3; OCI/AML3; OCI AML3; OCIAML3; Ontario Cancer Institute-Acute Myeloid Leukemia-3
DR   BTO; BTO:0004620
DR   CLO; CLO_0009853
DR   EFO; EFO_0006289
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioGRID_ORCS_Cell_line; 214
DR   BioSample; SAMN03473107
DR   BioSample; SAMN10988470
DR   cancercelllines; CVCL_1844
DR   CCTCC; GDC0216
DR   Cell_Model_Passport; SIDM00462
DR   ChEMBL-Cells; CHEMBL4295392
DR   ChEMBL-Targets; CHEMBL4296479
DR   Cosmic; 787467
DR   Cosmic; 975289
DR   Cosmic; 1012110
DR   Cosmic; 1127258
DR   Cosmic; 1245831
DR   Cosmic; 1319546
DR   Cosmic; 1557602
DR   Cosmic; 1582387
DR   Cosmic; 1696140
DR   Cosmic; 1779129
DR   Cosmic; 2131552
DR   Cosmic; 2306232
DR   Cosmic; 2750869
DR   Cosmic-CLP; 1290455
DR   DepMap; ACH-000336
DR   DSMZ; ACC-582
DR   DSMZCellDive; ACC-582
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 1290455
DR   GEO; GSM482512
DR   GEO; GSM887469
DR   GEO; GSM888549
DR   GEO; GSM1446756
DR   GEO; GSM1525022
DR   GEO; GSM1670296
DR   GEO; GSM2716711
DR   GEO; GSM2716712
DR   GEO; GSM2716774
DR   GEO; GSM2716775
DR   GEO; GSM2716776
DR   GEO; GSM2716777
DR   IARC_TP53; 30132
DR   LiGeA; CCLE_569
DR   LINCS_LDP; LCL-1066
DR   Lonza; 530
DR   PharmacoDB; OCIAML3_1184_2019
DR   Progenetix; CVCL_1844
DR   PubChem_Cell_line; CVCL_1844
DR   Ubigene; YC-C022
DR   Wikidata; Q54931742
RX   PubMed=2538684;
RX   PubMed=16079892;
RX   PubMed=16408098;
RX   PubMed=21552520;
RX   PubMed=22460905;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25984343;
RX   PubMed=26434589;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28109323;
RX   PubMed=29491412;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=31739141;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 28 hours (PubMed=25984343); ~35-40 hours (DSMZ=ACC-582).
CC   HLA typing: A*02:01,23:01; B*44:02,53:01; C*04:01,05:01 (PubMed=26589293).
CC   HLA typing: A*02:01:01,23:01:01; B*44:02:01,53:01:01; C*04:01:01,05:01:01 (DSMZCellDive=ACC-582).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 2978; DNMT3A; Simple; p.Arg882Cys (c.2644C>T); ClinVar=VCV000375882; Zygosity=Heterozygous (PubMed=26434589; PubMed=31160637; PubMed=31739141; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 7910; NPM1; Simple; p.Trp288Cysfs*12 (c.860_863dupTCTG); ClinVar=VCV000013998; Zygosity=Heterozygous (PubMed=16079892).
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=1.44%; East Asian, North=2.86%; East Asian, South=0%; South Asian=0.99%; European, North=55.94%; European, South=38.78% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): Cosmic-CLP; DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 8,13
ST   D16S539: 11,13
ST   D18S51: 12,18
ST   D19S433: 15,17
ST   D21S11: 29,30
ST   D2S1338: 17,21
ST   D3S1358: 16
ST   D5S818: 11,13
ST   D7S820: 9,10
ST   D8S1179: 10,12
ST   FGA: 22
ST   Penta D: 12,13
ST   Penta E: 11,13
ST   TH01: 8,9.3 (DSMZ)
ST   TH01: 8,10 (Cosmic-CLP; PubMed=25877200)
ST   TPOX: 8,11
ST   vWA: 17,18
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   57Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 41
//
RX   PubMed=2538684;
RA   Wang C., Curtis J.E., Minden M.D., McCulloch E.A.;
RT   "Expression of a retinoic acid receptor gene in myeloid leukemia
RT   cells.";
RL   Leukemia 3:264-269(1989).
//
RX   PubMed=16079892; DOI=10.1038/sj.leu.2403899;
RA   Quentmeier H., Martelli M.P., Dirks W.G., Bolli N., Liso A.,
RA   MacLeod R.A.F., Nicoletti I., Mannucci R., Pucciarini A., Bigerna B.,
RA   Martelli M.F., Mecucci C., Drexler H.G., Falini B.;
RT   "Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic
RT   expression of nucleophosmin.";
RL   Leukemia 19:1760-1767(2005).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=21552520; DOI=10.1371/journal.pone.0019169;
RA   Gu T.-L., Nardone J., Wang Y., Loriaux M., Villen J., Beausoleil S.A.,
RA   Tucker M., Kornhauser J.M., Ren J.-M., MacNeill J., Gygi S.P.,
RA   Druker B.J., Heinrich M.C., Rush J., Polakiewicz R.D.;
RT   "Survey of activated FLT3 signaling in leukemia.";
RL   PLoS ONE 6:E19169-E19169(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=26434589; DOI=10.1038/onc.2015.359;
RA   Ferreira H.J., Heyn H., Vizoso M., Moutinho C., Vidal E., Gomez A.,
RA   Martinez-Cardus A., Simo-Riudalbas L., Moran S., Jost E.,
RA   Esteller M.;
RT   "DNMT3A mutations mediate the epigenetic reactivation of the
RT   leukemogenic factor MEIS1 in acute myeloid leukemia.";
RL   Oncogene 35:3079-3082(2016).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28109323; DOI=10.1186/s13045-017-0396-0;
RA   Masetti R., Bertuccio S.N., Astolfi A., Chiarini F., Lonetti A.,
RA   Indio V., De Luca M., Bandini J., Serravalle S., Franzoni M.,
RA   Pigazzi M., Martelli A.M., Basso G., Locatelli F., Pession A.;
RT   "Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion
RT   gene.";
RL   J. Hematol. Oncol. 10:26.1-26.5(2017).
//
RX   PubMed=29491412; DOI=10.1038/s41388-018-0150-2;
RA   Gerlach D., Tontsch-Grunt U., Baum A., Popow J., Scharn D.,
RA   Hofmann M.H., Engelhardt H., Kaya O., Beck J., Schweifer N.,
RA   Gerstberger T., Zuber J., Savarese F., Kraut N.;
RT   "The novel BET bromodomain inhibitor BI 894999 represses
RT   super-enhancer-associated transcription and synergizes with CDK9
RT   inhibition in AML.";
RL   Oncogene 37:2687-2701(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=31739141; DOI=10.1016/j.leukres.2019.106270;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Fahnrich S., Hauer V.,
RA   Uphoff C.C., Zaborski M., Drexler H.G.;
RT   "DNMT3A R882H mutation in acute myeloid leukemia cell line SET-2.";
RL   Leuk. Res. 88:106270.1-106270.3(2020).
//